Quick, Sensitive Diagnostic Tests with CRISPR
The ability to quickly and cheaply detect minute amounts of specific nucleic acid (DNA and RNA) sequences could bring significant public health benefits. For example, it could be used to detect viral or bacterial infections in a population during outbreaks. Other possible uses include finding antibiotic-resistance genes in bacteria or tumor mutations in the body. Current methods for detecting nucleic acids involve trade-offs in sensitivity, specificity, simplicity, cost, and speed.
Drs. James J. Collins and Feng Zhang of the Broad Institute of MIT and Harvard developed a new approach by adapting the CRISPR system, which bacteria use to defend themselves from other microbes. CRISPR enzymes use short “guide RNAs” to identify specific target sequences to cleave. Zhang’s group previously discovered that one CRISPR enzyme, called Cas13a, has an interesting “collateral effect.” After being activated by its target RNA sequence, Cas13a goes on to indiscriminately slice other non-targeted RNA nearby.
The researchers took advantage of this property to design a CRISPR-based nucleic acid detection platform. To detect when a target sequence was present, they added “reporter” RNA designed to emit a signal when cut. Whenever Cas13a was activated, it would go on to cut the reporter RNA and emit a signal. The study was funded in part by NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Mental Health (NIMH). The team described their approach online in Science on April 13, 2017.
The scientists first tested Cas13a enzymes from different bacteria to identify which had the best RNA-guided cutting activity. As amounts of DNA and RNA in samples can be minute, the researchers applied a technique called recombinase polymerase amplification, which can amplify nucleic acids without special equipment. Another enzyme could also be added to the reaction to convert DNA to RNA for Cas13a detection.
The team called this system SHERLOCK. Tests showed that SHERLOCK could detect RNA or DNA molecules at minute levels called attomolar levels. Established nucleic acid detection approaches can be similarly sensitive, but SHERLOCK gave more consistent results.
The researchers demonstrated several potential uses. SHERLOCK was able to detect specific strains of Zika and Dengue virus. It could detect Zika virus in serum, urine, and saliva from patients. It could distinguish pathogenic strains of bacteria. It could distinguish single base differences in DNA extracted from human saliva. Finally, it could detect cancer mutations among DNA fragments at levels like that found in patient blood.
Notably, SHERLOCK yielded comparable results when its components were freeze-dried, reconstituted, and tested on glass fiber paper. The scientists calculated that a paper test could be designed and created in a matter of days for as little as $0.61 per test. These qualities highlight the potential of this system for diagnostic field applications.
“We can now effectively and readily make sensors for any nucleic acid, which is incredibly powerful when you think of diagnostics and research applications,” Collins says. “The scientific possibilities get very exciting very quickly.”
This article has been republished from materials provided by NIH. Note: material may have been edited for length and content. For further information, please contact the cited source.
Biological Fingerprint of Tuberculosis Meningitis Discovered in ChildrenNews
Children with tuberculosis meningitis have a biological fingerprint that can be used to assess the severity of the condition, help decide the best course of treatment, and provide clues for novel treatments.READ MORE
Exosomes Offer Significant Potential in Detecting and Treating DiseaseNews
Exosomes - tiny biological nanoparticles which transfer information between cells - offer significant potential in detecting and treating disease, the most comprehensive overview so far of research in the field has concluded.READ MORE
FDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple Non-Small Cell Lung Cancer TherapiesNews
Oncomine Dx Target Test returns results in days, helping physicians rapidly develop treatment plans for the most common form of lung cancer.
Comments | 0 ADD COMMENT
3rd World Congress on Human Genetics & Genetic Disorders
Oct 20 - Oct 21, 2017